Full US approval of Gilead’s Tecartus was the only positive decision last month.
ApexOnco Front Page
Recent articles
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA mutants, as well as wild types.
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
A son of glembatumumab vedotin has just started its phase 1 study.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
The company will start its confirmatory bexobrutideg study in June.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
The group impresses in ovarian and endometrial cancers.
